Identifying early progressors of Alzheimer's disease using a blood test.
Screening ADNI patient cohorts to identify a sub-population that are AD early progressors in validating the prognostic ability of the Alzosure Predict blood test, 6 years in advance of current methods
['FUNDING_SBIR_2'] · DIADEM US, INC. · NIH-10688164
This study is looking for people with Alzheimer's who might be showing early signs of the disease, using a new blood test called Alzosure Predict, to see if it can help spot Alzheimer's earlier than current methods, which could lead to better treatment options.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DIADEM US, INC. (nih funded) |
| Locations | 1 site (PALO ALTO, UNITED STATES) |
| Trial ID | NIH-10688164 on ClinicalTrials.gov |
What this research studies
This research aims to identify a specific group of patients with Alzheimer's disease who show early signs of progression, using a new blood test called Alzosure Predict. The study will screen patient cohorts from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to validate the effectiveness of this blood test, which could potentially detect Alzheimer's disease years before current diagnostic methods. By focusing on early detection, the research seeks to improve treatment options and patient outcomes. Participants will undergo blood tests and assessments to help establish the prognostic ability of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are in the early stages of progression.
Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnosis of Alzheimer's disease, allowing for timely interventions.
How similar studies have performed: Previous research has shown promise in using blood tests for early detection of Alzheimer's disease, indicating that this approach may be viable.
Where this research is happening
PALO ALTO, UNITED STATES
- DIADEM US, INC. — PALO ALTO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AGUS, SHMUEL — DIADEM US, INC.
- Study coordinator: AGUS, SHMUEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome